Literature DB >> 18790562

Glucose avidity of carcinomas.

Alvaro D Ortega1, María Sánchez-Aragó, Daniel Giner-Sánchez, Laura Sánchez-Cenizo, Imke Willers, José M Cuezva.   

Abstract

The cancer cell phenotype has been summarized in six hallmarks [D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (1) (2000) 57-70]. Following the conceptual trait established in that review towards the comprehension of cancer, herein we summarize the basis of an underlying principle that is fulfilled by cancer cells and tumors: its avidity for glucose. Our purpose is to push forward that the metabolic reprogramming that operates in the cancer cell represents a seventh hallmark of the phenotype that offers a vast array of possibilities for the future treatment of the disease. We summarize the metabolic pathways that extract matter and energy from glucose, paying special attention to the concerted regulation of these pathways by the ATP mass-action ratio. The molecular and functional evidences that support the high glucose uptake and the "abnormal" aerobic glycolysis of the carcinomas are detailed discussing also the role that some oncogenes and tumor suppressors have in these pathways. We overview past and present evidences that sustain that mitochondria of the cancer cell are impaired, supporting the original Warburg's formulation that ascribed the high glucose uptake of cancer cells to a defective mitochondria. A simple proteomic approach designed to assess the metabolic phenotype of cancer, i.e., its bioenergetic signature, molecularly and functionally supports Warburg's hypothesis. Furthermore, we discuss the clinical utility that the bioenergetic signature might provide. Glycolysis is presented as the "selfish" pathway used for cellular proliferation, providing both the metabolic precursors and the energy required for biosynthetic purposes, in the context of a plethora of substrates. The glucose avidity of carcinomas is thus presented as the result of both the installment of glycolysis for cellular proliferation and of the impairment of mitochondrial activity in the cancer cell. At the end, the repression of mitochondrial activity affords the cancer cell with a cell-death resistant phenotype making them prone to malignant growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790562     DOI: 10.1016/j.canlet.2008.08.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

1.  Long-standing statin therapy and the risk of new-onset diabetes in the elderly: collateral damage caused by preventive medicine?

Authors:  Luca Mascitelli; Mark R Goldstein
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

Review 2.  Tumor cell metabolism: an integral view.

Authors:  Susana Romero-Garcia; Jose Sullivan Lopez-Gonzalez; José Luis Báez-Viveros; Dolores Aguilar-Cazares; Heriberto Prado-Garcia
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

3.  Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis.

Authors:  Tomo-O Ishikawa; Indracanti Prem Kumar; Hidevaldo B Machado; Koon-Pong Wong; Donna Kusewitt; Sung-Cheng Huang; Susan M Fischer; Harvey R Herschman
Journal:  Mol Oncol       Date:  2010-02-02       Impact factor: 6.603

4.  The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.

Authors:  Hengning Ke; Rebecca Harris; Jonathan L Coloff; Jane Y Jin; Benjamin Leshin; Paula Miliani de Marval; Shiying Tao; Jeffrey C Rathmell; Russell P Hall; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

5.  PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Authors:  Omran Abu Aboud; Dallas Donohoe; Scott Bultman; Mark Fitch; Tim Riiff; Marc Hellerstein; Robert H Weiss
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-25       Impact factor: 4.249

6.  Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC.

Authors:  Isabel Vilaseca; Ximena Terra; Francesc Xavier Avilés-Jurado; Carmen Muñoz; Carla Meler; Joan Carles Flores; Josep Gumà; Ester Benaiges; Josefina Mora; Mercedes Camacho; Xavier León
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-31       Impact factor: 2.503

7.  Equating salivary lactate dehydrogenase (LDH) with LDH-5 expression in patients with oral squamous cell carcinoma: An insight into metabolic reprogramming of cancer cell as a predictor of aggressive phenotype.

Authors:  Tajindra Singh Saluja; Anita Spadigam; Anita Dhupar; Shaheen Syed
Journal:  Tumour Biol       Date:  2015-11-15

8.  Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats.

Authors:  Angelo Pietro Femia; Cristina Luceri; Simona Toti; Augusto Giannini; Piero Dolara; Giovanna Caderni
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

9.  Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.

Authors:  Fenglian Ren; Hong Wu; Yunlong Lei; Haiyuan Zhang; Rui Liu; Yong Zhao; Xiancheng Chen; Dequan Zeng; Aiping Tong; Lijuan Chen; Yuquan Wei; Canhua Huang
Journal:  Mol Cancer       Date:  2010-04-19       Impact factor: 27.401

10.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.